Literature DB >> 14734738

Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response.

Michael J Palmowski1, Luciene Lopes, Yasuhiro Ikeda, Mariolina Salio, Vincenzo Cerundolo, Mary K Collins.   

Abstract

Lentiviral vectors can efficiently transduce a variety of nondividing cells, including APCs. We assessed the immunogenicity of a lentiviral vector encoding the melanoma Ag NY-ESO-1 in HLA-A2 transgenic mice. Direct i.v. injection of NY-ESO-1 lentivirus induced NY-ESO-1(157-165)-specific CD8(+) cells, detected ex vivo with an A2/H-2K(b) chimeric class I tetramer. These NY-ESO-1(157-165)-specific CD8(+) cells could be expanded by boosting with an NY-ESO-1 vaccinia virus and could kill NY-ESO-1(157-165) peptide-pulsed targets in vivo. Such direct lentiviral vector injection was similar in potency to the injection of in vitro-transduced dendritic cells (DC). In addition, human monocyte-derived DC transduced by the NY-ESO-1 lentivirus stimulated an NY-ESO-1(157-165)-specific specific CTL clone. These data suggest that direct lentiviral transduction of DC in vivo might provide a powerful immunotherapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734738     DOI: 10.4049/jimmunol.172.3.1582

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

Review 2.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.

Authors:  Yukai He; Jiying Zhang; Cara Donahue; Louis D Falo
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

4.  Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Authors:  Andreas Pichlmair; Sandra S Diebold; Stephen Gschmeissner; Yasuhiro Takeuchi; Yasuhiro Ikeda; Mary K Collins; Caetano Reis e Sousa
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 5.  Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector.

Authors:  Yukai He; Louis D Falo
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  Programming the next generation of dendritic cells.

Authors:  Richard G Carroll; Carl H June
Journal:  Mol Ther       Date:  2007-05       Impact factor: 11.454

Review 7.  Lentivirus as a potent and mechanistically distinct vector for genetic immunization.

Authors:  Yukai He; Louis D Falo
Journal:  Curr Opin Mol Ther       Date:  2007-10

Review 8.  Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.

Authors:  Yukai He; David Munn; Louis D Falo
Journal:  Expert Rev Vaccines       Date:  2007-12       Impact factor: 5.217

9.  Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy.

Authors:  Katarzyna Karwacz; Sayandip Mukherjee; Luis Apolonia; Michael P Blundell; Gerben Bouma; David Escors; Mary K Collins; Adrian J Thrasher
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Authors:  Haiyan Xiao; Yibing Peng; Yuan Hong; Lei Huang; Z Sheng Guo; David L Bartlett; Ning Fu; David H Munn; Andrew Mellor; Yukai He
Journal:  J Immunol       Date:  2013-04-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.